Restoring mucosal Treg balance and clearing the dysbiotic biofilm
Phase 1 sealed the wall and silenced the alarm. The mucosal barrier is rebuilt, tight junctions are reforming, and NF-kB has been pulled off the gas pedal. But the gut you're walking into Week 5 with is structurally repaired and immunologically untrained. The T-cells that spent months — or years — reacting to translocated LPS and food antigens haven't unlearned that reflex. And underneath the new mucosa, in the lumen and the crypts, there's almost always a residual population of biofilm-protected pathogens that survived Phase 1 untouched.
Phase 2 addresses both. Thymosin Alpha-1 re-educates the adaptive immune system from the top down. LL-37 strips the biofilm so the regulatory work has something clean to regulate. This is the layer the practitioner corpus consistently flags as the difference between "symptoms came back at month four" and sustained remission.
What's actually happening at the cellular level
The three-layer model the practitioner corpus uses for gut-driven autoimmune protocols frames it cleanly: Layer 1 — repair the wall (BPC-157). Layer 2 — fuel cutoff (KPV inhibits NF-kB translocation, upregulates IL-10). Layer 3 — retrain (TA-1 educates T-cells, recalibrates immune intelligence). Phase 1 was Layers 1 and 2. Phase 2 is Layer 3, with a biofilm-disruption layer running underneath it.
Thymosin Alpha-1 is a synthetic surrogate for thymic output. The thymus — your master T-cell training organ — begins involuting after puberty and is nearly inactive by age 50. TA-1 doesn't reverse the involution structurally. It compensates for it. The peptide provides the molecular signals the shrinking thymus can no longer produce in adequate quantities, restoring T-cell maturation, dendritic cell priming, and — critically for gut autoimmunity — Treg/Th17 balance at the mucosal surface. Restored Tregs are the cells that tell the rest of the immune system "this antigen is not a threat, stand down." Without that signal, every translocated peptide from Week 4 onward becomes a fresh trigger.
The cytokine signature you're chasing: upregulated IL-10, downregulated TNF-α and IL-6, restored CD4/CD8 ratio. Practitioner consensus is that meaningful immune modulation from TA-1 takes 8-12 weeks — this is a slow-grinding remodel, not a Week 1 symptom flip. The published work on TA-1 in post-acute SARS-CoV-2, autoimmune contexts, and hepatitis B all show the same shape: lymphocyte counts and Treg populations recover gradually across multi-month windows.
LL-37 is doing structural demolition underneath that immunological retraining. Biofilms — organized bacterial communities embedded in extracellular polymer matrix — are why standard antibiotic courses fail in chronic gut presentations. The pathogens inside a mature biofilm are shielded from both antibiotics and your own immune cells. LL-37, the human cathelicidin, attacks biofilms at a structural level that conventional antimicrobials cannot reach. This is why the practitioner corpus places LL-37 — not metronidazole, not rifaximin — as the missing piece in SIBO, parasitic, and dysbiotic presentations that keep recurring after antibiotic cycles.
The cycling discipline matters. LL-37 is a broad-spectrum antimicrobial. Running it open-ended will degrade beneficial flora alongside the pathogenic biofilms. The substrate is unanimous: 4-6 week cycles, then off.
The Phase 2 stack (Week 5-10)
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Thymosin Alpha-1 | 1.6 mg | SubQ | 2x/week | 🟢 Expert | Maintenance dosing per the standard gut-immune protocol. Run continuous through Week 10 and into maintenance. |
| Thymosin Alpha-1 (acute alt.) | 1.0 mg | SubQ | Daily, Week 5-6 loading | 🟢 Expert | Optional loading window if Phase 1 markers showed persistent inflammation. Step down to 1.6 mg 2x/week from Week 7. |
| LL-37 | 50-100 mcg | SubQ | Daily | 🟢 Expert | Run Week 5 through Week 8-10. Hard stop at 6 weeks max — do not exceed. |
| LL-37 (high-dose acute) | 200 mcg | SubQ | 2x/day | 🟣 Experimental | Reserved for confirmed SIBO, parasitic, or biofilm-heavy presentations. Practitioner-corpus dose. Shorter cycle (3-4 weeks). |
| BPC-157 (continued) | 250-500 mcg | SubQ, abdomen-near | Daily (maintenance taper) | 🟢 Expert | Carry the Phase 1 BPC-157 forward at the lower end of range. The wall is rebuilt but the repair signaling is still load-bearing while LL-37 disrupts biofilms. |
KPV from Phase 1 sunsets at Week 4-5. The NF-kB inhibition work is done; what comes next is regulatory, not anti-inflammatory.
What you should feel
The substrate is specific that the felt timeline of Phase 2 is gradient, not stepwise. Expect:
- Week 5-6 (LL-37 loading): Possible mild die-off symptoms — fatigue, transient brain fog, occasional loose stool for 3-7 days. This is biofilm disruption releasing endotoxin into a lumen that's now sealed (good — it can be cleared rather than translocated). Symptoms should resolve into Week 6.
- Week 7-8: First subjective TA-1 signal. Practitioner corpus describes it as "fewer reactive days" rather than a discrete event — fewer flares from inconsistent meals, faster recovery from training, reduced post-prandial fatigue.
- Week 8-10: Treg-mediated tolerance becoming the new baseline. Disease-specific antibody titers (anti-TPO if Hashimoto-overlapping, ANA, tissue transglutaminase) should begin trending. Practitioner consensus is that meaningful TA-1 effect lands at 8-12 weeks — Week 10 is the lower edge of that window.
What's NOT happening yet
- You are not in remission at Week 10. Phase 2 is the immune-retraining intervention — it sets up the maintenance protocol (Chapter 10), it does not replace it. Antibody titers trending down is the goal, not antibodies at zero.
- LL-37 is not a "kill phase" in the herbal-protocol sense. It is biofilm demolition. The bulk of the actual pathogen clearance is done by your now-trained immune system. Don't stack berberine, oregano, or aggressive botanicals on top — you'll wipe the beneficial flora you spent Phase 1 protecting.
- Don't extend LL-37 past 6 weeks "because it's working." The substrate is unanimous on the cycle cap. Beneficial flora disruption from extended cathelicidin exposure is the failure mode. If Week 6 markers show residual dysbiosis, the next move is a 4-week LL-37 washout followed by a second short cycle — not a continuous run.
- TA-1 is not a Week 1 molecule. First-time users sometimes step down or quit at Week 6 because "nothing's happening." Nothing visible is happening — Treg education and cytokine signature remodeling are sub-symptomatic until they aren't. The published clinical work and the practitioner corpus both anchor the meaningful-effect window at 8-12 weeks minimum, with full benefit extending to 12-24 weeks of continued dosing.
- The labs at Week 10 are not the verdict. ANA, anti-TPO, ESR, CRP, CBC with differential, and disease-specific antibodies are what the corpus tracks at Week 8 and Week 16. Week 10 is mid-stream. Slope matters more than absolute values until the Week 16 pull.
- TB-500 is not in this phase either. Connective tissue and acute injury pairings (the Wolverine Stack) are a different protocol family. For immune retraining of the gut, the named combination is TA-1 + LL-37 with BPC-157 carried forward. Phase 3 maintenance (Chapter 10) is where the long-term low-dose schedule gets defined.
The practitioner corpus is clear on the sequence — rebuild the wall, silence the fire, retrain the immune system, then clear the biofilm. Run Phase 2 through Week 10. Pull the Week 16 labs before you make any decision about Phase 3.